Radisys Introduces Programmable Media Analytics to Monetize 5G & Edge Cloud Applications
23.2.2023 16:00:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced the addition of Engage Media Analytics within the acclaimed Engage Digital Platform (EDP). Engage Media Analytics is a comprehensive solution that provides Communication Service Providers (CSPs), System Integrators, and Enterprises with cost-effective low-code/no-code visual design tools to create Industry 4.0 applications with new AI-powered audio analytics and computer vision capabilities.
Engage Media Analytics’ application possibilities include notifying medical personnel when a patient in a wheelchair needs assistance or an elderly at-home patient has fallen from the bed; or identifying critical keywords or background sounds on an emergency call to augment the live agent discussion and help make life-saving decisions; detecting a fire in a factory, campus building, or other location and alerting emergency services personnel; monitoring retail shelves and combing customer identification, location, and live video to send money saving coupons to a frequent shopper’s phone as they near a location with promotional items; and many other Industry 4.0 services.
The Engage Media Analytics solution offers a unique combination of capabilities:
- Off-the-shelf models including people and object counting, object and sound detection and classification, and biometric authentication. Engage Media Analytics also supports model customization and new model creation.
- Ability to create trigger actions based on insights derived from the media stream whether through other communication capabilities in the EDP, including voice and video calling, creating an on-the-fly conference, sending alerts, and recording, as well as interworking with external systems for initiating business processes in enterprise workflow tools.
- Distributed deployment of services spanning public and private clouds, network edge infrastructure, and on enterprise premises, enabling applications that demand low latency, cost and bandwidth-efficient network utilization for local breakout, and ensuring data privacy and security.
Alan Quayle, Founder TADHack, TADSummit, said: “The programmable communications industry (CPaaS) is evolving from a focus on connectivity to understanding the content of communications through programmable media analytics. Actionable intelligence and compliance are important in delivering innovative new services. The all-in-one Engage Digital Platform delivers AI-based actionable intelligence that enables service providers to deliver business efficiencies for their customers' mission-critical applications.”
Radisys’ Engage Media Analytics can be deployed on distributed edge cloud and integrates with public or private 4G/5G RAN and core network functions such as Network Exposure Function (NEF), abstracting complexities for application developers to productize Industry 4.0 applications quickly and cost-effectively.
Al Balasco, Head of Media and Application Solutions, Radisys, said: “The convergence and simultaneous maturity of multiple technologies like AI-based computer vision, 5G, edge cloud, and programmable communications opens new opportunities for service providers and system integrators to collaborate with enterprises in their digital transformation. Engage Media Analytics lets service providers combine the advantages of the bandwidth, low latency, Internet of Things (IoT) connectivity, and edge cloud resources to monetize public and private 5G networks and deliver customized solutions like predictive surveillance in smart cities, remote monitoring of enterprise campuses, business workflow automation for product quality assurance, traffic monitoring, and more.”
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.radisys.com.
Radisys’ Engage Digital Platform is an award-winning programmable communications platform. Radisys' capacity-based versus consumption-based licensing approach for all products in the Engage Digital Platform offers a truly disruptive economic model relative to alternative programmable communications solutions. It dramatically improves the total cost of ownership (TCO) savings to 70% and greater over competitive cloud-based programmable communications and video analytics solutions, allowing service providers to reap the benefits.
For more information, visit www.engagedigital.ai.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005336/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom